Sareum is a drug discovery and development company, focused on small molecule therapeutics for the treatment of cancer. Their unique approach involves the use of structure-based drug design to create targeted therapies that have the potential to improve patient outcomes. With a strong pipeline of novel drug candidates in various stages of development, Sareum is committed to advancing cutting-edge treatments for cancer patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

8 Patents

#112 in Cambridge

#2,096 in United Kingdom

Cambridge, United Kingdom

Sareum Limited

Forward Citations = 13

15 inventors:

John Charles Reader (8 out of 20 patents)

John Mark Ellard (2 out of 3 patents)

Helen Boffey (2 out of 2 patents)

4. Susanne Taylor (2 out of 2 patents)

5. Andrew David Carr (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sareum Limited. Retrieved from https://idiyas.com/company/sareum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

7 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]